2 results
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…
Approved WMORecruiting
Primary Objective: Major amputation rate after 12-months of follow-upSecondary Objectives: - Amputation-free survival- Health-related quality of life- Complete wound healing- Pain scores- Need for additional (vascular) interventions- Cost-…